PBM
KYTX icon

Propel Bio Management’s Kyverna Therapeutics KYTX Stock Holding History

Propel Bio Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.59M Sell
644,421
-22,245
-3% -$185K 3.52% 8
2025
Q4 		$6.27M Buy
+666,666
New +$4.95M 5.35% 6

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Propel Bio Management's KYTX Position: Q1 2026 in Review

Propel Bio Management reduced its Kyverna Therapeutics (KYTX) stake by 3.3% in Q1 2026, selling an estimated $185K and leaving 644,421 shares worth $5.59M. The position accounts for 3.52% of the portfolio, ranked #8.

Propel Bio Management first reported a position in KYTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $6.27M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Propel Bio Management held 644,421 shares of Kyverna Therapeutics worth $5.59M as of Q1 2026.
  • Propel Bio Management sold 22,245 Kyverna Therapeutics shares in Q1 2026, an estimated $185K.
  • Kyverna Therapeutics made up 3.52% of Propel Bio Management's portfolio in Q1 2026, its #8 holding.
  • Propel Bio Management first reported a position in Kyverna Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Propel Bio Management's Kyverna Therapeutics position peaked at $6.27M in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Propel Bio Management's 13F filing for Q1 2026, filed 14 May 2026.